Apr 02, 08
|
| NEW STORY |
| 10:33 ET |
ActivBiotics' Intellectual Property Assets, Including Drug Product Candidates, Sold for $3.5 Million
|
|
Mar 06, 08
|
| 08:00 ET |
ActivBiotics Receives FDA Orphan Drug Designation for Superoxide Dismutase Mimetic, M40403, in Oral Mucositis of Cancer
|
|
Mar 05, 08
|
| 08:00 ET |
ActivBiotics Set to Sell Proprietary Assets, Including Drug Product Candidates, on March 14, 2008
|
|
Feb 25, 08
|
| 09:15 ET |
ActivBiotics Proposes Development Strategy for Its Novel Rifamycin Antibiotics
|
|
Feb 19, 08
|
| 08:00 ET |
ActivBiotics Outlines a Clinical Path Forward to Examine if Rifalazil Is Superior to Azithromycin in the Treatment of Chlamydia STD
|
|
Feb 05, 08
|
| 08:24 ET |
ActivBiotics Receives Orphan Drug Designation from the European Medicines Agency for Superoxide Dismutase Mimetic, M40403, in Oral Mucositis Indication
|
|
Jan 28, 08
|
| 14:03 ET |
ActivBiotics Completes Sale of Fixed Assets; Expands Due Diligence Initiative for the Sale of Intellectual Property, Including Drug Product Candidates
|
|
Jan 15, 08
|
| 08:37 ET |
ActivBiotics Extends Deadline to March 14, 2008 for the Sale of Proprietary Assets, Including Drug Product Candidates
|
|
Dec 18, 07
|
| 11:33 ET |
ActivBiotics Sells Proprietary Assets, Including Drug Product Candidates
|
|
Nov 07, 07
|
| 11:45 ET |
Rifalazil Trial (PROVIDENCE-1) Fails to Provide Significant Clinical Benefit in Patients With Peripheral Arterial Disease
|
|
Oct 24, 07
|
| 07:00 ET |
ActivBiotics to Present Results of Pivotal Study in the Treatment of Peripheral Arterial Disease at AHA Meeting
|
|
May 01, 07
|
| 07:00 ET |
ActivBiotics, Inc. Appoints Steven C. Gilman Chairman and CEO
|
|
Feb 14, 07
|
| 07:00 ET |
ActivBiotics Announces Initiation of Phase II Study in Carotid Atherosclerosis
|
|
Sep 26, 06
|
| 07:00 ET |
ActivBiotics, Inc. Announces Completion of Patient Enrollment in Phase III Clinical Trial in Peripheral Arterial Disease
|
|
Aug 14, 06
|
| 16:16 ET |
ActivBiotics, Inc. Files Registration Statement for Proposed Initial Public Offering
|
|
Mar 29, 06
|
| 15:04 ET |
ActivBiotics Announces Change in Board of Directors
|
|
Mar 10, 06
|
| 17:13 ET |
ActivBiotics, Inc. to Sponsor Satellite Symposium at 2006 ACC Meeting
|
|
Mar 02, 06
|
| 07:02 ET |
ActivBiotics, Inc. to Present at SG Cowen & Co.'s 26th Annual Health Care Conference
|
|
Feb 01, 06
|
| 07:04 ET |
ActivBiotics Receives FDA Fast Track Status for Rifalazil in Peripheral Arterial Disease
|
|
Jan 11, 06
|
| 08:03 ET |
ActivBiotics and Metaphore Complete Merger Creating Late-Stage Company Addressing Serious Infections and Inflammation
|
|
Dec 20, 05
|
| 10:32 ET |
ActivBiotics Inc. Presentation at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
|
|
Dec 14, 05
|
| 08:00 ET |
ActivBiotics, Inc. and Metaphore Pharmaceuticals, Inc. Sign Definitive Merger Agreement
|
|
Dec 06, 05
|
| 08:03 ET |
Michael Hanson joins ActivBiotics Board
|
|
May 18, 05
|
| 10:45 ET |
ActivBiotics, Inc. Establishes Canadian Operations, Appoints Suzanne Cadden to Senior Management Team and Jeff Courtney to the Board of Directors
|
|
Jan 10, 05
|
| 06:30 ET |
ActivBiotics, Inc. Appoints Glenn Kazo to Senior Management Team as Clinical Programs and New Lead Compound Advance
|
|
Nov 01, 04
|
| 10:54 ET |
ActivBiotics, Inc. Announces Positive Phase 2 Results on its Investigational Antibacterial Agent, Rifalazil
|
|
Mar 16, 04
|
| 07:05 ET |
ActivBiotics Announces Senior Management Changes
|
|
Aug 18, 03
|
| 08:06 ET |
Ronald Farquhar to Serve as VP, Pre-clinical at ActivBiotics
|
|
Aug 04, 03
|
| 07:02 ET |
ActivBiotics Raises $26.4 Million in Series B Financing
|
|
Jul 28, 03
|
| 13:54 ET |
ActivBiotics Secures Exclusive License to Patents Covering Arterial Chlamydial Granuloma Therapy in Atherosclerosis from University of Washington
|
|
Jul 15, 03
|
| 16:25 ET |
ActivBiotics Announces Patent Issuances Covering Combination Anti-Chlamydial Therapies to Treat Chronic Inflammatory Diseases
|
|
Jul 02, 03
|
| 16:17 ET |
ActivBiotics Announces Expanded Intellectual Property Coverage for Its Lead Antibiotic Compound, Rifalazil, First of a New Generation of Long Acting Ansamycins
|
|
Apr 14, 03
|
| 07:01 ET |
ActivBiotics Appoints John Mekalanos to Scientific Advisory Board
|
|
Oct 15, 02
|
| 07:01 ET |
ActivBiotics and DepoMed Announce Agreement to Develop New Product for the Treatment of Acute and Chronic Gastrointestinal Diseases
|
|
Mar 27, 02
|
| 13:38 ET |
ActivBiotics Announces Key Appointments to Its Senior Management Team
|
|
|